ACUTE REPETITIVE SEIZURES MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2024-2031)

Market Size and Trends

Global acute repetitive seizures market is estimated to be valued at USD 3.10 Bn in 2024 and is expected to reach USD 7.12 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

To learn more about this report, request a free sample copy

 Rising geriatric population suffering from neurological disorders, growing awareness about the disease condition, new product approvals and launches, and increasing research and development activities by key market players are expected to boost demand for acute repetitive seizures treatment. Increasing government initiatives and support for improving access to neurodevelopment is expected to offer lucrative opportunities for the market growth. However, lack of patient awareness, high cost of treatment, and stringent regulatory frameworks are can hamper the market growth.

Market Driver – Increasing Awareness about Seizure Management and Treatment

Rising prevalence of neurological disorders increases  focus on managing the symptoms and associated conditions effectively. Acute repetitive seizures pose serious health risks if not addressed promptly through proper treatment. Various epilepsy foundations and patient advocacy groups have intensified their efforts to educate people about seizure types, triggers, and available therapeutic options. Their awareness campaigns emphasize the importance of seeking medical help for recurrent seizures instead of overlooking the problem. Healthcare professionals too are more vocal about the need for timely and coordinated care to prevent complications. This has motivated more patients and caregivers to engage with neurologists and utilize anti-seizure drugs or emergency medications to curb episodic seizure activity. The push for hastening appropriate clinical management of acute events is compelling individuals to rely on treatment pathways involving anti-convulsants.

Market Concentration and Competitive Landscape

To learn more about this report, request a free sample copy

The soaring patient base inevitably increases the probability of acute repetitive seizures occurring among epileptic patients. As acute repetitive seizures can potentially be life-threatening if not addressed promptly with proper medication, there has been huge demand for anti-epileptic drugs and other treatment options. Several innovative drug formulations, advanced therapeutics such as neurostimulation devices and gene therapies, and efficient healthcare infrastructure are aiding efficient management of acute repetitive seizures. Increasing prevalence of epilepsy is becoming a major concern worldwide, and is one of the key factors supplementing the growth of the acute repetitive seizures market. According to the World Health Organization, around 50 million people globally suffer from epilepsy, making it one of the most common neurological disorders. This rising patient pool of epilepsy is directly fueling the need for effective management of acute repetitive seizures.

To learn more about this report, request a free sample copy

Side effects associated with the treatments available for acute repetitive seizures can hamper the growth of the acute repetitive seizures market. The medications used for controlling acute repetitive seizures such as benzodiazepines, antiepileptic drugs, and others often cause serious adverse effects that significantly impact the patient's quality of life. Some common side effects include tiredness, dizziness, blurred vision, nausea, vomiting, behavioral changes, and others.  In some severe cases, the side effects of these drugs can even lead to life-threatening issues like bronchospasm, Stevens-Johnson syndrome and serious allergic reactions.

Market Opportunity – Expanding Applications in Developing Countries

Expanding applications in developing countries in acute repetitive seizures market represents a significant opportunity for the market growth in the near future. Developing nations across Asia, Latin America, Africa and parts of Eastern Europe are experiencing rapidly increasing incidences of epilepsy and recurrent seizures. According to the World Health Organization, epilepsy prevalence is expected to rise by over 18% in India and parts of sub-Saharan Africa between 2020-2030 as populations’ age and risk factors associated with trauma and infectious diseases remain high in these regions.

To learn more about this report, request a free sample copy

Drug Type segment is sub-segmented into benzodiazepines, antiepileptic drugs, barbiturates, others (late phase drugs, etc.). Benzodiazepines sub-segment is estimated to hold 35.2% of the market share in 2024, owing to its proven efficacy in controlling acute repetitive seizures. Benzodiazepines like diazepam and lorazepam work quickly to stop seizure activity and provide rapid relief for patients experiencing recurrent seizures. Their mechanism of action involves enhancing the effect of the inhibitory neurotransmitter GABA, which reduces neuronal excitability in the brain and stops seizures from propagating. Numerous clinical studies have demonstrated that benzodiazepines can terminate acute repetitive seizures within 5-10 minutes in the majority of patients. Their fast onset of action provides benzodiazepines a key advantage over other anticonvulsant drugs that may take hours to take full effect.

Insights, By Route of Administration: Oral administration segment dominates due to convenience

Route of administration segment is sub-segmented into oral, injectable, others. Oral sub-segment is estimated to hold 38.3% of the market share in 2024 due to the convenience it offers to patients. For epileptics experiencing acute repetitive seizures, oral medications are highly preferable as these are non-invasive and easy for patients to self-administer during a seizure episode. This allows for rapid treatment without requiring a medical professional's assistance or visit to a healthcare setting. Not having to travel for injection administration expands treatment access. Oral anticonvulsants are also convenient for outpatient treatment following an acute seizure episode.

Insights, By Distribution Channel: Hospital pharmacies dominates due to insurance reimbursement

Distribution Channel segment is sub-segmented into hospital pharmacies, retail pharmacies, online pharmacies. Hospital pharmacies sub-segment is estimated to hold 33.1% of the market share in 2024 owing to favourable insurance reimbursement structures. Acute seizure episodes often require emergency medical assistance and treatment, which frequently occurs in hospital settings. Most medical insurance plans in major markets have provisions for full or partial hospitalization coverage including costs of prescribed drugs obtained via hospital pharmacies. This makes hospital treatment an affordable option for episodic seizure management even for patients on tight budgets. With medical costs covered, there exists high demand for management within hospitals versus other channels.

Regional Insights

To learn more about this report, request a free sample copy

North America remains the dominant region in the global acute repetitive seizures market and is estimated to hold 41.3% of the market share in 2024 due to several factors such as strong healthcare infrastructure, rising incidence of neurological disorders, and presence of leading market players in the region. The U.S. accounts for the major share due to availability of advanced treatment options and growing patient awareness about epilepsy care. Moreover, favorable reimbursement policies have enabled patients to access high-quality care, thus, driving the market growth

Asia Pacific is considered as the fastest growing market for acute repetitive seizures. Countries such as China, India, and Japan are anticipated to offer lucrative opportunities for market growth in the near future due to increasing healthcare spending, improving access to diagnosis and treatment facilities, and rising geriatric population susceptible to seizures. The economic growth in Asia has opened opportunities for international players to collaborate with local companies and establish manufacturing facilities, especially in China and India, thus, driving the regional market growth.

Market Report Scope

Key Developments

• In January 2022, Neurelis, Inc., a biopharmaceutical company, signed an exclusive agreement with Aculys Pharma to commercialize and develop VALTOCO in the Asia Pacific region. Aculys Pharma is a Japan-based company that focuses on commercializing and developing innovations in psychiatry and neurology.
• In July 2020, Takeda Pharmaceutical Company Limited, a pharmaceutical company, announced a global partnership with Ovid Therapeutics, a biotechnology company, to develop and commercialize Soticlestat, a potentially effective treatment for rare epilepsy syndromes, including certain forms of acute recurrent seizures.
• In April 2020, UCB S.A., a biopharmaceutical company, announced an agreement to acquire the rights to Proximagen’s Midazolam Nasal Spray (USL261), an anti-epilepsy drug (AED) developed as an intended rescue treatment for acute repetitive seizures (ARS, also known as serial, recurrent or cluster seizures) in patients with epilepsy

*Definition: Acute repetitive seizures, also known as cluster, crescendo, or sequential seizures, are defined as episodes of increased seizure activity occurring in patients with refractory epilepsy who are already receiving stable regimens of anticonvulsants. These seizures lie between isolated seizures and status epilepticus, and if left untreated, these may progress to status epilepticus.

Market Segmentation

• Drug Type Insights (Revenue, USD Bn, 2019 - 2031)
  • Benzodiazepines
  • Antiepileptic drugs
  • Barbiturates
  • Others (Late Phase Drugs, etc.)
•  Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
  • Oral
  • Injectable
  • Others
•  Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Regional Insights (Revenue, USD Bn, 2019 - 2031)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
    • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Neurelis, Inc.
  • Bausch Health Companies Inc.
  • Alexza Pharmaceuticals, Inc.
  • VERITON PHARMA
  • UCB S.A.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Sanofi
  • GSK plc
  • Eisai Co., Ltd.
  • H. Lundbeck A/S
  • Cognizance Biomarkers, LLC
  • F. Hoffmann-La Roche Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals LLC
  • Sun Pharmaceutical Industries Ltd.